Decreased serum levels of sCD163, especially in cases of thyroid dysfunction or adrenal insufficiency, indicates that CD163+ macrophages have been activated and effector cells have been recruited to the target organ, both of which underly the development of irAEs by nivolumab. This evidence concerns the gene CD163 and Adrenal insufficiency.